Biopharmaceutical company Lysogene (Paris:LYS) on Friday revealed that its cash and cash equivalents amounted to EUR26.5m as of 31 December 2019.
This marks a decline when compared with cash and cash equivalents of EUR29.1m as of 30 September 2019.
The 2019 cash and cash equivalents include the payments from Sarepta Therapeutics Inc related to the milestone payment and development cost reimbursement triggered by dosage of the first patient in AAVance, the Phase 2/3 clinical trial of LYS-SAF302 in MPS IIIA. The license and collaboration agreement with Sarepta Therapeutics Inc generated in 2019 revenues of EUR12.0m.
At the end of 2019, the cash position is in line with the company's expectations and allows to serenely advance the development programme of the 16th patient under its Phase 2/3 clinical trial of LYS-SAF302 in MPS IIIA, said Karen Aiach, founder and CEO.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study